PAP19 Antibody

Prostatic Acid Phosphatase (PAP) Overview

PAP is a glycoprotein enzyme highly expressed in prostate tissue and overproduced in prostate cancer. It serves as a biomarker and therapeutic target. Antibodies targeting PAP aim to stimulate immune responses against prostate cancer cells .

Monoclonal Antibodies

• Anti-PAP IgG1/IgM (Source ):

  • Recognizes distinct antigenic determinants on PAP.

  • Specificity: IgG1/IgM antibodies show higher specificity for PAP compared to IgG2a/IgG3, which cross-react with nonprostatic acid phosphatases.

  • Applications: Immunohistochemistry, competitive-binding assays, and refining diagnostic tests for prostate cancer.

Recombinant Antibodies

• ab109004 (EPR4067) (Source ):

  • Rabbit-derived monoclonal antibody targeting human PAP.

  • Applications: Western blot (50 kDa band), IHC, ICC/IF.

  • Validation: Detects PAP in prostate adenocarcinoma lysates and tissues.

DNA Vaccines

• A phase 1 trial used a DNA vaccine encoding PAP to induce cytotoxic T-cell responses in prostate cancer patients. Booster immunizations amplified PAP-specific IFNγ-secreting T cells, correlating with delayed disease progression .

Mutated PAP Vaccines

• A 2022 study developed a MutPAP42mer peptide vaccine with CAF®09 adjuvant. It enhanced CD8+ T-cell cytotoxicity against PAP-expressing tumor cells in mice and human PBMCs .

ELISPOT and Flow Cytometry

• PAP-specific T-cell responses were quantified using IFNγ ELISPOT assays .

• Dextramer™ technology identified circulating PAP-135-143 epitope-specific CD8+ T cells in patients .

Research Gaps

• No studies or commercial products reference "PAP19 Antibody." The nomenclature may refer to an uncharacterized clone, a typographical error, or a proprietary compound not yet published.

Recommendations

To advance this inquiry:

1. Verify the exact nomenclature ("PAP19") with the source or patent databases.

2. Explore antibodies targeting PAP epitopes p18-26, p112-120, or p299-307, which have validated immune responses .

3. Consider CAF®09-adjuvanted vaccines for therapeutic applications .